800 Hudson Way NW Suite 2304 Huntsville, AL, 35806 United StatesLocated at the HudsonAlpha Institute for Biotechnology (HAIB) in Huntsville, AL USA, iRepertoire was the first company to develop and patent multiplex amplification technologies for comprehensive and inclusive analysis of the adaptive immune receptor repertoire (AIRR) with a focused purpose of advancing applications for translational and clinical research. Over the past 15 years, iRepertoire has pioneered and developed new and enabling amplification technologies to bring forward the promise to one day leverage the AIRR as an early and ultrasensitive biomarker of human health and disease. Our founders have been at the forefront of this field since its inception with 11 published patents related to immune repertoire amplification, sequencing and analysis. We support both the academic clinical research community and also biopharmaceutical drug developers, globally, with applications in immuno-oncology, infectious diseases, autoimmunity, cell and gene therapy. Our state-of-the-art molecular facilities are Good Clinical Laboratory Practices (GCLP) compliant, CLIA certified (for certain assays) and aligned to meet the current and future needs of both clinical researchers and biopharmaceutical drug developers. iRepertoire customers choose us over other service labs for our comprehensive and highly competitive offerings that include: - Expert support from initial study design through iterative, exploratory data analysis - Comprehensive 7-chain TCR and BCR analysis - GCLP compliance with complete transparency and full data ownership for all workflows - CLIA certification for a selection of testing workflows - Flexible analysis for either DNA or RNA - Physically paired receptor chains from rare immune cell subpopulations - Targeted gene-expression panel for focused immunophenotyping - Flow cytometry expertise for analysis, bulk repertoire, and single cell Each of our analyses have long-established, analytically validated protocols with greater than five years of experience supporting commercial client service projects. Our significant storage capacity supports 6,000 samples under liquid nitrogen; 15,000 samples in -150 C freezers and over 65,000 samples in -80 C freezers. Our commitment to data transparency ensures that all generated data are fully accessible for further analysis. iRepertoire has an unwavering commitment to provide high quality immune repertoire data from patient samples for clinical research. This is underscored by a physical segregation of PCR-based workflows with retrograde airflow throughout our facility to mitigate any potential for sample cross contamination. Additionally, we have prepared a Business Continuity and Disaster Preparedness Plan (IRP-0006) to fully document how we ensure operational continuity in the event of an emergency. This plan details how we would preserve original patient sample materials, intermediates and the resultant data in the event of a power outage or other emergency. All data is backed up in the cloud through a third party vendor offsite to ensure all data is protected from loss. Our Quality Management System adheres to GCLP standards ensuring that our innovative products and services are of the highest quality, meeting or exceeding customer requirements and expectations. Our commitment to Continual Quality Improvement (CQI) includes ongoing staff training, state of the art equipment and systems to control product supply and project completion effectively and efficiently in a timely, accurate, coherent, relevant, and professional manner. At iRepertoire, we are committed to fostering a diverse and inclusive workplace, emphasizing that our strength comes from our diversity. We are proud of our diverse team which is composed of 3% African American, 24% Asian, and 72% Caucasian individuals of whom 76% are female and 21% are male. Our C-level leadership positions are held equally by men (50%) and women (50%), reflecting our serious commitment to gender equality and leadership diversity. We pledge to continually strive for diversity, equity, and inclusion across every aspect of our business operations and decision-making processes.